Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 3;14(9):2103–2111. doi: 10.1158/1535-7163.MCT-15-0305

Figure 5.

Figure 5

pSTAT1 is not a favorable prognostic indicator in HNSCC patients treated with adjuvant cisplatin and panitumumab. Tumor specimens from patients with advanced, high risk HNSCC were collected prior to adjuvant radiation, cisplatin, and panitumumab, then stained for p-S727-STAT1 (A) and p-Y701-STAT1 (B). Patients were divided into high or low phospho-STAT1 groups (above or below mean), and survival was assessed.